WO2001079838A1 - Device for detecting analytes related to sample ph - Google Patents
Device for detecting analytes related to sample ph Download PDFInfo
- Publication number
- WO2001079838A1 WO2001079838A1 PCT/US2001/011437 US0111437W WO0179838A1 WO 2001079838 A1 WO2001079838 A1 WO 2001079838A1 US 0111437 W US0111437 W US 0111437W WO 0179838 A1 WO0179838 A1 WO 0179838A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- holding structure
- analyte
- sample
- kit
- assay
- Prior art date
Links
- 239000012491 analyte Substances 0.000 claims abstract description 67
- 238000003556 assay Methods 0.000 claims description 82
- 210000003296 saliva Anatomy 0.000 claims description 71
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 70
- 238000012360 testing method Methods 0.000 claims description 61
- 239000000523 sample Substances 0.000 claims description 59
- 229960003920 cocaine Drugs 0.000 claims description 36
- 239000000700 radioactive tracer Substances 0.000 claims description 29
- 239000012488 sample solution Substances 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 16
- 238000003018 immunoassay Methods 0.000 claims description 12
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 12
- 229960001252 methamphetamine Drugs 0.000 claims description 12
- 238000001139 pH measurement Methods 0.000 claims description 10
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 150000002894 organic compounds Chemical class 0.000 claims description 4
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 claims description 3
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 claims description 3
- 229940012189 methyl orange Drugs 0.000 claims description 3
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 claims description 3
- 231100000614 poison Toxicity 0.000 claims description 3
- 239000003440 toxic substance Substances 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 2
- 238000011109 contamination Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims 8
- 239000003086 colorant Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 description 45
- 229940079593 drug Drugs 0.000 description 44
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 210000002381 plasma Anatomy 0.000 description 19
- 239000012528 membrane Substances 0.000 description 12
- 239000011230 binding agent Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000036765 blood level Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000003255 drug test Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 239000012042 active reagent Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000002967 competitive immunoassay Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000012070 reactive reagent Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- KZFBHCCLJSAHBQ-UHFFFAOYSA-N Benzoylecgonine Natural products CN1C2CCC1C(C(C2)OC(=C)c3ccccc3)C(=O)O KZFBHCCLJSAHBQ-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- -1 enzymes Chemical class 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000012206 semi-quantitative assay Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/816—Alkaloids, amphetamines, and barbiturates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/901—Drugs of abuse, e.g. narcotics, amphetamine
Definitions
- This invention relates to chemical analysis tests, and, in particular, a device for detecting the presence or quantity of analytes while also measuring the pH of sample solutions containing the analytes.
- an active reagent is chosen from a group of reagents that are reactive with the analyte.
- reactive reagents include substances that react with the analyte, enzymes or enzymatic substrates of the analyte, or binding reagents of the analyte, such as antibodies or antigens.
- results of analyte testing can be used to diagnose medical conditions and to measure the concentration of drugs or toxic substances in a human or animal subject. Analyte test results can also be used to monitor appropriate levels of therapeutic agents or for other purposes.
- the presence or quantity of the analyte depends upon the pH of the solution. ' :.pH can be measured in a variety of different ways, including via color changes in organic compounds . Such compounds include methyl red, methyl orange, bromphenol blue, etc.
- the pH can assist the person administering the test in correlating the cocaine or methamphetamine in the saliva to the blood levels of the drug. See Malamud, D., Saliva as a Diagnostic Fluid, Br. Med. J. 305 : 201-208 (1990); Mandel, I. D., The Diagnostic Uses of Saliva, J. Oral Pathol . Med.
- This invention involves a device for the concurrent measurement of pH and an analyte in solution where the presence or quantity of the analyte is related to the pH of the solution.
- solutions could include, but are not limited to, saliva, urine, whole blood, serum plasma, mucous or mixtures of other substances in liquid.
- the device is a single unit that contains a pH measurement section, an assay section, and a color coded pH comparison section that allows the pH to be interpreted. The simplicity of the device and the ability to quickly and accurately make appropriate measurements with pH correlation is a significant improvement over previous devices.
- Fig. 1 depicts one embodiment of the invention that uses a membrane containing reagents for detecting an analyte.
- Fig. 2 depicts a different embodiment of the invention that utilizes, a lateral flow immunoassay for detecting an analyte.
- Fig. 3 depicts one embodiment of the invention where the pH of the specimen and the presence or quantity of two analytes in one sample solution can be determined in one unit on two separate assay strips.
- Fig. 4 depicts another embodiment of the invention where the pH and analytes of two different drugs can be tested on the same assay strip.
- Fig. 5 depicts another embodiment of the invention where the pH and analytes of two different drugs can be tested on a flow-through assay device.
- Fig. 1 depicts one embodiment of the invention that uses a membrane containing reagents for detecting an analyte.
- Fig. 2 depicts a different embodiment of the invention that utilizes, a lateral flow immunoassay for
- FIG. 6 depicts a preferred embodiment of the device that contains a color chart designed to aid in semi-quantitatively determining the amount of a drug in saliva.
- Fig. 7 depicts a wrapper surrounding the holding structure within a kit.
- Fig. 8 depicts a sample cup that can be included in a kit.
- Fig. 9 depicts a dropper that can be used to place saliva drops on the testing device of the kit.
- a combination pH and analyte measuring device 7 or 9 is contained within a single holding structure 6.
- the device 7 or 9 is preferably made from a non-toxic, disposable material that prevents subsequent contamination with toxic substances or potentially infectious body fluids after disposal.
- an assay section 8 or 20 for measuring the presence or quantity of an analyte in a sample solution and also a section 10 for measuring the pH of the same solution.
- a color coded pH comparison chart 12 contained within the holding structure.
- Both the assay section 8 or 20 and the pH section 10 are housed within the same holding structure 6.
- the assay section 8 or 20 contains at least one active reagent for the testing of the analyte.
- the active reagent is chosen from a group of reagents that are reactive with the analyte.
- reactive reagents include reactive chemicals of the analyte, enzymes or enzymatic substrates of the analyte, and binding agents of the analyte, such as antibodies or antigens.
- a flow-through immunoassay comprises a porous membrane having a binding reagent immobilized on the membrane. An absorbent material is placed on one side of the membrane. When a sample containing an analyte is applied to the membrane, the sample flows through the membrane by capillary movement. The analyte is then bound to the binding reagent.
- a flow-through immunoassay further comprises applying a tracer that is another binding reagent of the analyte with a label for detecting the bound analyte.
- the binding reagents of the membrane and tracer are selected from a group consisting of antibodies, antigens, protein A, protein G, receptor proteins, etc.
- the label can be selected from a group of detectable substances, including enzymes, radioactive isotopes, and particular color particles.
- Suitable membranes include glass fiber, polyvinylidene difluoride, polycarbonate, nitrocellulose, nylon, etc. See U.S. Patent No. 5,155,022.
- Reagents for the assay of analytes can be placed at the assay section by different means, including embedding, absorption, and covalent bond formation between the reagent and the supporting material, which are familiar to those skilled in the art. See U.S. Patent Nos. 5,602,040; 5,559,041; 4,943,522; and 5,591,645. Measuring the signal intensity of the test area with an instrument can make quantitative or semiquantitative assays of analytes in the sample. Depending on the property of the label of the tracer, a measuring instrument that is capable of reading the signal of the tracer is chosen for the purpose.
- Such instrument may be a gamma counter for radioactive isotope labeled tracers, a fluorescence reader for fluorophore labeled tracers, and spectrophotometer for reading the reflection of colored assay areas in assays involving particular particle labeled tracers.
- a calibration curve/dose response curve of the assay can be used for calculating the analyte concentration.
- the resulting color test areas can be read visually to give semi-quantitative determinations of the analytes made through comparisons to a color chart.
- Different intensity color areas are printed on a color chart.
- the color intensity of the test area is matched with the color area on the chart, which corresponds to a value of the analyte quantity in the sample.
- the pH section 10 involves utilizing organic compounds that have varied color changes in solutions of different pH. Such compounds include methyl red, methyl orange, bromphenol blue, etc.
- These reagents can be placed in the pH test unit as a solution or dry powder. The dry reagents can be imbedded into a porous matrix as a pH strip that is commercially available.
- the pH test section 10 and the assay section 8 or 20 are positioned within the same holding structure 6.
- the pH test section 10 and the assay section 8 or 20 are arranged within the holding structure to allow relatively simultaneous performance of both the pH test and assay analysis.
- the material for the holding structure 6 may be chosen from a group of solid materials, including plastic, metal, cellulose, or other similar materials known to those skilled in the art.
- the sample solution is placed on a membrane in the assay section 8 that contains reagents for detecting the analyte.
- the sample is also placed on a pad containing reagents for measuring pH 10.
- the pH chart 12 has three different indicator areas 14, 16, 18. Each color of the indicator area represents one pH value. The pH of the sample solution is measured by matching the color observed on the pH pad 10 with that of the pH chart 12.
- the assay section of the device is a lateral flow immunoassay strip 20.
- the lateral flow assay section comprises a bibulous assay strip having four zones: • a sample addition zone 22, a tracer zone 23, a test zone 24, and a reagent- receiving zone 26.
- a movable tracer is supported at tracer zone 23.
- a binder is immobilized at test zone 24.
- sample addition zone 22 An assay sample applied to sample addition zone 22 will flow through zone 23 and zone 24 until being absorbed at receiving zone 26 by capillary action.
- the presence or quantity of the analyte in the sample is determined by measuring the presence or quantity of tracer bound at test zone 24.
- lateral flow assay There are three forms of lateral flow assay: sandwich assay and two forms of competitive assay.
- the lateral flow immunoassay is a sandwich immunoassay with the tracer at zone '23 and an immobilized binder at zone 24 being capable of binding the analyte. If the sample contains the analyte, the analyte will bind with the tracer at the tracer zone 23, and the binder at the test zone 24 will then capture the analyte-tracer complex.
- a detectable amount of analyte is the amount of analyte capable of producing a detectable amount of tracer signal at test zone 24. If the sample does not contain the analyte, the tracer will flow through test zone 24 and no detectable amount of tracer will be bound at test zone 24.
- the lateral flow immunoassay is a competitive immunoassay, with the tracer being a labeled analyte or an analogue of the analyte, and the binder being a binder of both the analyte and the tracer.
- the analyte and the tracer compete for binding sites at test zone 24.
- the quantity of tracer bound at test zone 24 is inversely proportional to the quantity of analyte in the sample solution.
- the lateral flow immunoassay is a competitive immunoassay, with the tracer being a labeled binding reagent of the analyte, and the binder at test zone 24 being an analogue of the analyte that also binds the tracer.
- the analyte in the sample competes with the binder at test zone 24 for binding sites of the tracer.
- the quantity of tracer bound at test zone 24 is inversely proportional to the quantity of analyte in the sample solution.
- the binding reagents in a lateral flow immunoassay are selected from a group consisting of antibodies, antigens, protein A, protein G, receptor proteins, etc.
- the label can be selected from a group of detectable compounds, including enzymes, radioactive isotopes, and particular color particles.
- Suitable bibulous materials include glass fiber, polyvinylidene difluoride, polycarbonate, nitrocellulose, nylon, etc.
- Reagents for the assay of analytes can be placed at the test zone by different means, including embedding, absorption, and covalent bond formation between the reagent and the supporting material, which are familiar to those skilled in the art.
- a hydrophobic divider separates the agents of the pH test section 10 and the assay section 8 or 20.
- the assay protocol of this embodiment comprises applying the sample solution separately to both the pH test section 10 and assay section 8 or 20.
- the holding structure 72 contains a pH section 82, a sample application section 84 and an assay measurement section 75.
- the assay measurement section is divided into a test section 76 and a control section 74.
- a color chart 78 is provided to compare the color intensity that shows in the test section 76 to known quantities of an analyte.
- a pH chart 80 is provided to compare the color that appears in the pH section 82 with the chart 80.
- the result of the detected analyte may be calibrated using a formula involving the measured pH of the sample solution.
- the presence or quantity of certain drugs in saliva is dependent upon the pH of the saliva.
- Saliva testing is useful because non-protein bound plasma fractions of drugs can easily be measured in saliva.
- saliva samples are assayed to estimate the blood concentration of the drugs, the saliva drug concentrations can be converted to blood drug concentrations with the formula involving the pH value of the saliva sample.
- D' is the ionized form of the drug and HD is the non-ionized form of the drug.
- the pKa is fixed. Therefore, the pH of the solution determines the extent of ionization of the drug.
- the predicted ratio of drug concentration in saliva and drug concentration in plasma can be calculated knowing the saliva and plasma pH, and the pKa of the drug from the following:
- S/P [1 + ⁇ o (PHs - PKa >] / [l + ⁇ o ⁇ ! *-***>]
- S/P [1 + ⁇ o (pKa -P Hs) ] / [1 + ⁇ 0 ⁇ PKa - H P>]
- pHs saliva pH
- pHp plasma pH
- pKa the pKa of the drug.
- the pH of healthy human plasma is relatively stable, the pH of saliva is the most important factor affecting [A] S /[A] P ratio. In many cases it is not necessary to test the pH of plasma to calculate the predicted plasma drug level.
- saliva drug concentration levels can be correlated to plasma levels, saliva assay results can also be useful within themselves. For example, the cut-off level for determining whether a person is under the influence of cocaine can be set in connection with the pH of the saliva sample.
- Saliva testing has several advantages over invasive blood testing. Saliva testing is not painful, is virtually risk free to all involved, is simple and quick, and is more economic. Saliva testing in conjunction with saliva pH testing is advantageous over saliva testing alone because it allows accurate prediction of blood levels of analytes based on saliva testing result and saliva pH.
- the saliva and pH testing device claimed in this application is a single holding structure that contains both the assay section and the pH testing section. Such a single unit that contains both tests has several advantages over separate testing of saliva for analytes and pH. First, the single device is more convenient for use than two separate tests. In addition, pH can be tested immediately before it rises due to release of dissolved carbon dioxide.
- kits that contains the device consisting of the holding structure, the pH section, the pH chart, the assay section and instructions for determining ' the blood concentration of the analyte from the measured pH and the analyte concentration of the saliva sample.
- Another preferred embodiment of the invention allows the pH and analytes of several different drugs to be tested in one unit from the same sample solution.
- the presence or quantity of cocaine, marijuana and/or other drugs can be tested from one saliva sample in one single unit, as depicted in Fig. 3.
- the sample is applied to an application zone 30, which is in flow communication with two separate assay strips 33 and 35 and a pH section 10.
- the sample flows by capillary action through a tracer zone on each strip 32 and 34 and continues to two separate assay zones 36 and 38 where the tracer is bound depending on the presence or quantity of the analyte in the assay sample. Non-bound portions of the sample then flow into receiving zones 40 and 42.
- a pH comparison section 12 is present. All of the elements of both assay strips 33 and 35, the application zone 30, the pH section 10, and the pH comparison chart 12 are contained within the same holding structure 11. This embodiment can be altered to allow for the addition of more assay strips to accommodate tests for more than two drugs.
- Fig. 4 illustrates another embodiment 48 used for multi-drug testing that uses a single assay strip 44.
- the sample is applied to the application zone 43 and then flows to the tracer zone 50.
- the analytes then bind to either assay zone 52 or assay zone 54, depending on which drug is being bound at that assay area.
- the unbound portion of the sample then flows into the receiving zone 56.
- the pH section 10 is in flow communication with the assay strip 44. All components of the assay strip 44, the pH section 10, and the pH comparison chart 12 are contained within the same holding structure 46.
- This embodiment can be altered to allow for the addition of more assay areas on the strip to accommodate tests for more than two drugs.
- FIG. 5 Another embodiment of the invention that allows for multi-drug testing is a flow-through assay device as depicted in Fig. 5.
- the sample solution is placed on the assay section 62 and flows to two assay zones 64 and 66.
- Zone 64 is the binding zone for one drug
- zone 66 is the binding zone for the second drug. Additional binding zones for other drugs can be added if needed.
- a labelled tracer that is another binding reagent of the analyte is applied to assay zone 64 or 66, and it makes the bound analyte detectable.
- a separate sample is applied to the pH section 10. All components of the device, including the pH comparison chart, are contained within a single holding structure 60.
- saliva would be collected from a person using a saliva collection device, such as the device described in U.S. Patent Application Serial No. 09/183,295, Tatum et al., allowed November 14, 1999.
- the saliva would then be transferred from the collection device to the sample addition zone 22 of the single assay strip 20.
- the solution migrates to the pH section 10 and the tracer zone 23, then to the assay membrane test zone 24.
- the pH value of the sample can be read at approximately 30 seconds after application, and the drug test result can be read on the assay test zone 24 approximately five minutes after sample application.
- Fig. 6 This test kit is for use in testing cocaine in a saliva sample and deriving the corresponding concentration in plasma. Since cocaine secretion from blood to saliva strongly depends on the pH of saliva, the value is factored into the calculation of plasma cocaine concentration from measured saliva cocaine concentration. A semi-quantitative result from plasma cocaine concentration is obtained at the end of the assay.
- Each rapid oral fluid test cassette 70 included in this test kit consists of a lateral flow assay strip, a color intensity chart 78, a pH test section 82, and a pH chart 80.
- the lateral flow assay strip consists of color dye labeled cocaine antibody and a nitrocellulose membrane coated with cocaine-Bovine Serum Antibody ("BSA") conjugate.
- BSA cocaine-Bovine Serum Antibody
- Plasma cocaine concentration in ng/ml Saliva cocaine concentration ng/ml ⁇ S/P ratio.
- the antibody used in this assay has less than 5% cross- reactivity with benzoylecgonine as compared with cocaine. No significant cross-reactivity was found with tetrahydrocannabinols, phencyclidine, methamphetamine, morphine, codeine, or ethanol.
- test result is for reference only. Positive result needs to be confirmed with GC/MS or other confirmatory methods .
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01924835A EP1277052A4 (en) | 2000-04-14 | 2001-04-06 | Device for detecting analytes related to sample ph |
NZ521712A NZ521712A (en) | 2000-04-14 | 2001-04-06 | Device for detecting analytes related to saliva sample pH for measuring drug concentration in blood |
AU2001251453A AU2001251453A1 (en) | 2000-04-14 | 2001-04-06 | Device for detecting analytes related to sample ph |
JP2001576453A JP2003531375A (en) | 2000-04-14 | 2001-04-06 | Detector for sample related to sample pH |
CA002404240A CA2404240A1 (en) | 2000-04-14 | 2001-04-06 | Device for detecting analytes related to sample ph |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/549,725 US6391261B1 (en) | 2000-04-14 | 2000-04-14 | Device for detecting analytes related to sample pH |
US09/549,725 | 2000-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001079838A1 true WO2001079838A1 (en) | 2001-10-25 |
Family
ID=24194151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/011437 WO2001079838A1 (en) | 2000-04-14 | 2001-04-06 | Device for detecting analytes related to sample ph |
Country Status (7)
Country | Link |
---|---|
US (1) | US6391261B1 (en) |
EP (1) | EP1277052A4 (en) |
JP (1) | JP2003531375A (en) |
AU (1) | AU2001251453A1 (en) |
CA (1) | CA2404240A1 (en) |
NZ (1) | NZ521712A (en) |
WO (1) | WO2001079838A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040052684A1 (en) * | 2002-09-14 | 2004-03-18 | Sinsky Jerome L. | Diagnostic kit and method of using same |
US20040053417A1 (en) * | 2002-09-14 | 2004-03-18 | Sinsky Jerome L. | Diagnostic device and method of using same |
DE10309349B4 (en) * | 2003-03-03 | 2005-11-10 | Micronas Holding Gmbh | Device for analyzing an analyte |
US7887750B2 (en) * | 2004-05-05 | 2011-02-15 | Bayer Healthcare Llc | Analytical systems, devices, and cartridges therefor |
US20060133338A1 (en) * | 2004-11-23 | 2006-06-22 | Interdigital Technology Corporation | Method and system for securing wireless communications |
US7993283B1 (en) * | 2007-07-23 | 2011-08-09 | Pop Test LLC | Method and apparatus for non-invasive analysis of saliva |
JP5982920B2 (en) * | 2012-03-22 | 2016-08-31 | 王子ホールディングス株式会社 | Absorbent articles |
JP5940861B2 (en) * | 2012-03-30 | 2016-06-29 | アークレイ株式会社 | Saliva secretion promoting device |
JP6117499B2 (en) * | 2012-08-23 | 2017-04-19 | 株式会社Kri | Lifestyle-related disease determination support method using saliva test |
US20160018424A1 (en) * | 2013-03-01 | 2016-01-21 | Compassionate Analytic Inc. | Methods for cannabinoid quantification |
US10073069B2 (en) | 2013-04-23 | 2018-09-11 | Cordant Research Solutions, Llc | Systems and methods to determine body drug concentration from an oral fluid |
WO2019169309A1 (en) * | 2018-03-02 | 2019-09-06 | Berger Russell Jay | Methods, apparatuses and kits for rapid testing of traumatic brain injuries |
WO2024053464A1 (en) * | 2022-09-06 | 2024-03-14 | 日東電工株式会社 | Analysis system and analysis method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5069878A (en) * | 1987-03-24 | 1991-12-03 | Ehrenkranz Joel R L | Integrity preserving and determining urine sample collection apparatus |
US5501985A (en) * | 1990-07-18 | 1996-03-26 | Abbott Laboratories | Analyte-substitute reagent for use in specific binding assay methods, devices and kits |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH065631Y2 (en) * | 1987-03-05 | 1994-02-09 | ライオン株式会社 | Oral inspection tool |
CA1303983C (en) | 1987-03-27 | 1992-06-23 | Robert W. Rosenstein | Solid phase assay |
JPH0746107B2 (en) | 1987-04-27 | 1995-05-17 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Test method |
US4943522A (en) | 1987-06-01 | 1990-07-24 | Quidel | Lateral flow, non-bibulous membrane assay protocols |
JPH0199063U (en) * | 1987-12-24 | 1989-07-03 | ||
CA1331525C (en) * | 1988-05-19 | 1994-08-23 | Joel R. L. Ehrenkranz | Integrity preserving and determining urine sample collection apparatus |
US5252496A (en) | 1989-12-18 | 1993-10-12 | Princeton Biomeditech Corporation | Carbon black immunochemical label |
US5155022A (en) | 1991-02-08 | 1992-10-13 | Becton, Dickinson And Company | Assay for lyme disease |
US5714341A (en) * | 1994-03-30 | 1998-02-03 | Epitope, Inc. | Saliva assay method and device |
DE4444764A1 (en) * | 1994-12-16 | 1996-06-20 | Moell Claus Juergen | Body fluid analysis test kit, process for its manufacture and analysis process |
US5726062A (en) * | 1995-04-19 | 1998-03-10 | Konica Corporation | Method of detecting protein and a kit detecting protein using the same |
JPH095319A (en) * | 1995-06-20 | 1997-01-10 | Showa Shell Sekiyu Kk | Method and kit for detecting substance to be detected in urine |
JP3536268B2 (en) * | 1995-10-09 | 2004-06-07 | アークレイ株式会社 | Multi-item urine test paper |
US5989840A (en) * | 1997-05-29 | 1999-11-23 | Americare International Diagnostics, Inc. | Estimation of active infection by heliobacter pylori |
JP3786231B2 (en) * | 1997-07-31 | 2006-06-14 | 久光製薬株式会社 | Inspection device |
US6102872A (en) * | 1997-11-03 | 2000-08-15 | Pacific Biometrics, Inc. | Glucose detector and method |
JP2000009727A (en) * | 1998-06-24 | 2000-01-14 | Daikin Ind Ltd | Method for converting saliva component into blood component, device therefor an diagnostic equipment |
US6022326A (en) * | 1998-10-30 | 2000-02-08 | Lifepoint, Inc. | Device and method for automatic collection of whole saliva |
-
2000
- 2000-04-14 US US09/549,725 patent/US6391261B1/en not_active Expired - Fee Related
-
2001
- 2001-04-06 EP EP01924835A patent/EP1277052A4/en not_active Withdrawn
- 2001-04-06 CA CA002404240A patent/CA2404240A1/en not_active Abandoned
- 2001-04-06 JP JP2001576453A patent/JP2003531375A/en active Pending
- 2001-04-06 WO PCT/US2001/011437 patent/WO2001079838A1/en not_active Application Discontinuation
- 2001-04-06 NZ NZ521712A patent/NZ521712A/en unknown
- 2001-04-06 AU AU2001251453A patent/AU2001251453A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5069878A (en) * | 1987-03-24 | 1991-12-03 | Ehrenkranz Joel R L | Integrity preserving and determining urine sample collection apparatus |
US5501985A (en) * | 1990-07-18 | 1996-03-26 | Abbott Laboratories | Analyte-substitute reagent for use in specific binding assay methods, devices and kits |
Non-Patent Citations (1)
Title |
---|
See also references of EP1277052A4 * |
Also Published As
Publication number | Publication date |
---|---|
US6391261B1 (en) | 2002-05-21 |
CA2404240A1 (en) | 2001-10-25 |
NZ521712A (en) | 2004-04-30 |
EP1277052A4 (en) | 2005-06-01 |
JP2003531375A (en) | 2003-10-21 |
EP1277052A1 (en) | 2003-01-22 |
AU2001251453A1 (en) | 2001-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6248598B1 (en) | Immunoassay that provides for both collection of saliva and assay of saliva for one or more analytes with visual readout | |
US20160025752A1 (en) | Devices and methods for detecting and/or quantifying analytes in fluids | |
AU2005225088B8 (en) | Combination assay for alcohol and drugs of abuse | |
EP1891447B1 (en) | Two step lateral flow assay methods and devices | |
US6663831B2 (en) | “One-device” system for testing constituents in fluids | |
EP1307744B1 (en) | Assay apparatus | |
JP4623536B2 (en) | Oral fluid collection device | |
US5962336A (en) | Multi-test panel | |
US20120094303A1 (en) | Device for assaying analytes in bodily fluids | |
JP2009532675A (en) | Integrated screening and confirmation device | |
US6391261B1 (en) | Device for detecting analytes related to sample pH | |
De Giovanni et al. | Cozart Rapiscan system: our experience with saliva tests | |
CA2062900A1 (en) | Saliva testing and fingerprint identification method and device | |
US20030129673A1 (en) | Test apparatus for the detection of pharmacologically active compounds from saliva | |
AU2013229526B2 (en) | Method and device for detecting analytes | |
AU2006201307A1 (en) | Device for detecting analytes related to sample pH | |
JPH1151937A (en) | Inspection device | |
US20060088896A1 (en) | Diagnostic device for rapid determination of buprenorphine | |
AU2002338364B2 (en) | A "one-device" system for testing constituents in fluids | |
DSC-MET | SERATEC® Drug Screen MET | |
AU2002338364A1 (en) | A "one-device" system for testing constituents in fluids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2404240 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 521712 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001251453 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 576453 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001924835 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001924835 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 521712 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 521712 Country of ref document: NZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001924835 Country of ref document: EP |